Big announcement

1. NetEase Q4 net revenue was 27.14 billion yuan, an increase of 7% over the previous year

$NTES-S (09999.HK)$According to the release of financial reports for the fourth quarter and full year of 2023, NetEase's net revenue for Q4 of 2023 was 27.14 billion yuan, an increase of 7% over the previous year; net profit attributable to the company's shareholders was 6.582 billion yuan, compared to 3,953 billion yuan for the same period of the previous year.

The company announced that its board of directors approved a share repurchase plan totaling no more than $5 billion. As of December 31, 2023, the company had purchased approximately 7.2 million ADS shares, totaling approximately US$644 million.

2. NetEase Cloud Music's revenue in 2023 was 7.87 billion yuan. For the first time, it turned a loss into a profit for the whole year, and gross margin rose to 26.7%

$CLOUD MUSIC (09899.HK)$Disclosure of the 2023 results announcement. According to financial reports, NetEase Cloud Music's net revenue in 2023 was 7.87 billion yuan and net profit of 734 million yuan. NetEase Cloud Music's profit reached a record high for the full year of 2023, turning an annual loss into a profit for the first time. The gross margin rose from 14.4% in 2022 to 26.7% in 2023.

3. Pacific Shipping: 2023 turnover of US$2,297 billion, a year-on-year decrease of 30.02%

$PACIFIC BASIN (02343.HK)$Annual results for the year ended December 31, 2023 were announced, with turnover of US$2,297 million, a year-on-year decrease of 30.02%; profit attributable to shareholders of US$109 million, a year-on-year decrease of 84.41%.

4. Yuexiu Real Estate successfully competed for the Hefei Binke City plot with 1,414 billion yuan

$YUEXIU PROPERTY (00123.HK)$An announcement was issued on February 29, 2024. Through Wuhan Kangjing Industrial Investment Co., Ltd. (a subsidiary of the company that actually holds 99.638% of the shares) (Wuhan Kangjing), it successfully competed for Hefei Binke City plot BK202402 (Hefei Binke City plot) through a public listing of RMB 1,414 billion.

5. Fu Hong Han Lin: A supplementary application for new indications of Handayuan® was accepted by the State Drug Administration

$HENLIUS (02696.HK)$An announcement was issued. Recently, the China Drug Administration accepted a supplementary application for the addition of polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease, which was independently developed by the company.

Important matters

$SIRNAOMICS-B (02257.HK)$Unaware of the reasons for stock price fluctuations, there were no significant adverse changes in the Group's business operations and core product development

Earnings Report

$YUM CHINA (09987.HK)$Total revenue increased 15% to $10.98 billion in 2023

$NEW WORLD DEV (00017.HK)$Announcement of interim results: Core profit increased 12% to HK$4.866 billion with interim interest of HK$0.2 per share

$SUN HUNG KAI CO (00086.HK)$: The expected loss attributable to consolidated shareholders in 2023 is not more than HK$600 million

$SUPER HI (09658.HK)$Yingxi: Annual revenue is expected to increase by more than 21.9%

$HUABAO INTL (00336.HK)$: Expected profit before tax of 364 million to 464 million yuan in 2023

$CEB GREENTECH (01257.HK)$Profit Alert: Equity shareholders are expected to account for losses of over HK$300 million per year

Pharmaceutical Innovation

$LAEKNA-B (02105.HK)$: LAE102's new drug clinical trial application was accepted by the Drug Evaluation Center of the State Drug Administration

$FOSUN PHARMA (02196.HK)$: The holding subsidiary's supplementary application for drug registration was accepted

$SSY GROUP (02005.HK)$: Norepinephrine bitartrate has been approved and registered as an active ingredient for use in marketed formulations

$BAIYUNSHAN PH (00874.HK)$: The branch received a notice of approval for the marketing application of chemical raw materials

Acquisition and sale

$UCD (01599.HK)$Subsidiary company Guizhou Jingjian acquires land use rights and aboveground construction

Repurchase cancellation

$ASYMCHEM (06821.HK)$It is proposed to repurchase the company's A shares for 600 million to 1.2 billion yuan, and the repurchase price will not exceed 157 yuan/share

$AIA (01299.HK)$On February 29, it cost HK$141 million to repurchase 22.44 million shares

$HSBC HOLDINGS (00005.HK)$2,864,400 shares were repurchased at HK$172 million on February 28

$STANCHART (02888.HK)$On February 28, it cost £145.974 million to buy back 2.263,800 shares

$KUAISHOU-W (01024.HK)$On February 29, 706,300 shares were purchased at HK$31.1789 million

$HAOHAI BIOTEC (06826.HK)$A total of 1.347 million shares of the company's A shares have been repurchased

$SWIRE PACIFIC A (00019.HK)$On February 29, it spent HK$20.56 million to repurchase 314,500 shares

edit/ruby